Karyopharm Therapeutics Inc cuts to Neutral rating; cuts target price to $3 from $15
KPTI•Related News
BOJ Keeps Rates Steady, Delivers Hawkish Signal as Government Props Up Yen
TLT•
Daiichi Sankyo, AstraZeneca Datroway wins EU approval for first-line metastatic TNBC in non-immunotherapy patients
AZN•
NatWest Markets, NatWest Group subsidiary, posts H1 profit of £77 million
NWG•
Ukraine's Kyivstar lifts outlook again on strong earnings momentum
KYIV•
Regeneron Pharmaceuticals Inc <REGN.O>: JPMorgan raises target price to $900 from $850
REGN•